Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test may predict PRP success for arthritic knees

NCT ID NCT07617233

Knowledge-focused Sponsor: Utku Gürhan Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether a routine blood test can predict which patients with knee osteoarthritis will get good pain relief from platelet-rich plasma (PRP) injections. Researchers will enroll 120 people aged 40-60 with moderate knee arthritis. Each person will receive three PRP injections and be followed for 6 months. The goal is to see if simple blood markers of inflammation can help doctors decide who is most likely to benefit from this treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients aged 40 to 60 years presenting to the orthopedic clinic of the University of Kyrenia, Dr. Suat Gunsel Hospital, with symptomatic primary knee osteoarthritis of Kellgren-Lawrence grade 2 or 3, who are candidates for and scheduled to receive a course of intra-articular platelet-rich plasma for the index knee.

Ages

40 to 60 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 40 to 60 years * Symptomatic primary knee osteoarthritis, Kellgren-Lawrence grade 2 or 3 on weight-bearing radiographs * Body mass index below 40 * Candidate for and scheduled to receive a course of intra-articular platelet-rich plasma for the index knee * Able and willing to provide written informed consent and to attend the 6-month follow-up schedule Exclusion Criteria: * Systemic inflammatory or autoimmune disease * Active acute infection at the time of enrollment * Current anticoagulant or antiplatelet therapy, or current or recent chemotherapy * Any contraindication to platelet-rich plasma per the 2025 GRIIP recommendations * Intra-articular injection of the index knee within the previous 6 months * Inability to comply with the planned follow-up schedule

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Knee osteoarthritis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

osteoarthritis osteoarthritis, knee

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Knee osteoarthritis Osteoarthritis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of Kyrenia, Dr. Suat Gunsel Hospital - Department of Orthopaedics and Traumatology

    Kyrenia, Cyprus

More trials for these conditions

Other studies related to the condition(s) this trial covers.